Last 48 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.05 | — | 31.32 | — | — | — | — | — | — | 18.90 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9.40 | 20.08 | 3.88 | 60.62 | 234.96 | 76.26 | 39.10 | 47.42 | 59.88 | 3.74 | 144.54 | — | 7.11 | — | — | — | 42631.38 | 16.79 | — | — | — |
| — | -73.7% | -90.1% | +27.9% | +292.4% | +1939.1% | -72.9% | — | +742.6% | — | — | — | -100.0% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.10 | 9.67 | 6.68 | 8.61 | 7.07 | 4.59 | 2.73 | 1.98 | 2.43 | 2.93 | 3.22 | 2.03 | 2.62 | 1.91 | 1.79 | 1.29 | 1.01 | 1.39 | 1.41 | 1.48 | 1.69 |
| — | +110.8% | +144.3% | +334.4% | +191.5% | +56.6% | -15.1% | -2.6% | -7.4% | +53.5% | +80.0% | +57.9% | +159.5% | +37.3% | +26.7% | -13.1% | -40.3% | -49.6% | -54.3% | -45.2% | -2.5% | |
| P/FCF | — | — | — | — | — | — | — | — | 11.65 | — | 1.36 | 94.90 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 27.29 | — | — | — | — | — | — | 11.28 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 27.29 | — | — | — | — | — | — | 15.89 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | — | — | — | -1513500.0% | -265.7% | — | — | — |
| — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 0.0% | — | — | — | +100.0% | — | — | — | — | — | — | — | — | |
| Operating Margin | -1927.3% | -302.1% | 7.9% | -1321.5% | -4262.1% | -1721.6% | -1484.5% | -1956.6% | -1637.5% | 28.5% | -3051.1% | — | -23.9% | — | — | — | -1869700.0% | -342.2% | — | — | — |
| — | +82.5% | +100.5% | +32.5% | -160.3% | -6136.0% | +51.3% | — | -6744.4% | — | — | — | +100.0% | — | — | — | — | — | — | — | — | |
| Net Margin | -1971.6% | -269.7% | 12.4% | -1322.7% | -4252.4% | -1688.8% | -1622.4% | -1922.1% | -1389.4% | 21.6% | -3313.0% | — | -32.1% | — | — | — | -1874900.0% | -343.6% | — | — | — |
| — | +84.0% | +100.8% | +31.2% | -206.1% | -7921.1% | +51.0% | — | -4234.7% | — | — | — | +100.0% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.6% | -28.2% | 5.6% | -38.7% | -26.8% | -23.1% | -25.0% | -18.4% | -13.0% | 4.3% | -17.0% | -11.7% | -3.3% | -11.4% | -11.5% | -10.9% | -10.4% | -6.9% | -9.4% | -8.4% | -10.3% |
| — | -21.9% | +122.5% | -110.6% | -105.4% | -632.7% | -47.2% | -57.1% | -293.2% | +138.0% | -47.4% | -7.5% | +68.3% | -66.1% | -22.3% | -28.8% | -0.9% | +20.4% | +2.0% | -6.8% | -19.1% | |
| ROA | -36.6% | -6.0% | 1.3% | -10.1% | -8.8% | -8.8% | -10.6% | -8.6% | -6.6% | 2.3% | -11.2% | -10.2% | -2.9% | -10.1% | -10.3% | -9.9% | -9.6% | -6.4% | -8.7% | -7.6% | -9.2% |
| — | +31.1% | +112.3% | -17.8% | -32.6% | -483.7% | +6.1% | +15.6% | -128.3% | +122.6% | -8.7% | -3.4% | +69.6% | -58.1% | -19.1% | -30.0% | -4.6% | +16.7% | +0.0% | -5.8% | -16.3% | |
| ROIC | -99.2% | -62.2% | 6.3% | -56.4% | -34.8% | -26.0% | -21.7% | -18.0% | -15.3% | 6.2% | -18.9% | -17.0% | -2.9% | -11.7% | -12.8% | -11.1% | -9.7% | -7.0% | -9.9% | -9.1% | -14.2% |
| — | -139.4% | +129.2% | -213.4% | -127.4% | -519.3% | -14.7% | -5.6% | -424.4% | +152.9% | -48.1% | -54.1% | +70.0% | -68.5% | -29.3% | -22.0% | +31.4% | +59.8% | +48.4% | +59.6% | +43.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.14 | 0.12 | 0.14 | 0.10 | 0.07 | 0.07 | 0.05 | 0.05 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +93.8% | +77.2% | +150.0% | +109.3% | +215.1% | +151.6% | +137.3% | +122.1% | +24.4% | +44.1% | +32.0% | +31.3% | +45.7% | +40.1% | +34.8% | +32.1% | -8.8% | -9.1% | +24.9% | +21.6% | |
| Debt / EBITDA | — | — | 2.12 | — | — | — | — | — | — | 0.40 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.02 | 0.85 | 0.93 | 0.87 | 1.02 | 1.16 | 1.33 | 1.53 | 1.71 | 1.86 | 1.80 | 7.78 | 9.22 | 7.36 | 8.89 | 10.38 | 11.16 | 10.85 | 13.28 | 14.87 | 10.12 |
| — | -26.9% | -30.0% | -43.4% | -40.1% | -37.7% | -25.8% | -80.3% | -81.5% | -74.8% | -79.8% | -25.1% | -17.4% | -32.2% | -33.1% | -30.1% | +10.3% | -21.0% | -22.4% | -25.0% | -38.8% | |
| Quick Ratio | 1.02 | 0.85 | 0.93 | 0.87 | 1.02 | 1.16 | 1.33 | 1.53 | 1.71 | 1.86 | 1.80 | 7.78 | 9.22 | 7.36 | 8.89 | 10.38 | 11.16 | 10.85 | 13.28 | 14.87 | 10.12 |
| — | -26.9% | -30.0% | -43.4% | -40.1% | -37.7% | -25.8% | -80.3% | -81.5% | -74.8% | -79.8% | -25.1% | -17.4% | -32.2% | -33.1% | -30.1% | +10.3% | -21.0% | -22.4% | -25.0% | -38.8% | |
| Interest Coverage | -367.83 | -147.31 | 31.72 | -226.71 | -343.83 | — | -422.78 | -351.39 | -525.47 | 167.76 | -668.41 | -495.17 | -181.42 | -581.31 | -622.33 | -179.52 | — | -174.48 | -154.87 | -121.36 | -121.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACIU stock.
AC Immune S.A.'s current P/E is -5.0x. The average P/E over the last 1 quarters is 31.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AC Immune S.A.'s current operating margin is -1927.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AC Immune S.A.'s business trajectory between earnings reports.